Dysurgal

There is no image.

Atropine Sulfate

Method of action: Antispasmodic, Drugs For Functional Gastrointestinal Disorders, Mydriatic, Mydriatic-Cycloplegic, Ophthalmologicals

Treatment option: Iritis, Crossed Eyes, Slow Heart Rate, Poisoning

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dysurgal

Dysurgal is a prescription-only medicine formulated as an oral tablet, primarily used to relieve internal cramps and spasms by targeting the body's involuntary nervous signals. Its action works to restore comfortable function within affected organs by inducing smooth muscle relaxation.

Property	Description
Active Ingredient	Atropine Sulfate
Form	Oral Tablet
Pharmacological Class	Anticholinergic Agent (Antimuscarinic)
General Purpose	Relieves pain caused by smooth muscle spasms
Origin	Tropane Alkaloid Derivative

What Type of Medicine is Dysurgal and What Does It Contain?

Dysurgal belongs to the pharmacological class known as anticholinergic agents or antimuscarinics, and its sole active ingredient is Atropine Sulfate. This classification means it works by blocking the action of a key nerve chemical called acetylcholine on specific receptors.

The active substance, Atropine, is a naturally occurring compound related to the tropane alkaloid family, which is clinically recognized for its powerful, selective parasympatholytic action. As a single-ingredient product, Dysurgal's therapeutic profile is specifically differentiated by its concentrated focus on severe cholinergic blockade, which is beneficial for sudden, acute spasms such as renal or biliary colic.

What is the General Purpose of Anticholinergic Agents?

The general purpose of Dysurgal is to disrupt the excessive and often painful signals that cause the involuntary tightening or spasms of smooth muscle tissues, such as those found in the gastrointestinal and urinary tracts. It accomplishes this by acting as a competitive antagonist, effectively occupying the receiving sites (muscarinic receptors) that would normally trigger muscle contraction and glandular secretion.

Atropine is classified as an agent with vagolytic action, meaning it has the ability to inhibit the action of the vagus nerve. This confirms the drug's role in controlling internal organ activity and reducing hypersecretion, a specific benefit in managing conditions involving cramping and excessive fluid production.

Key Characteristics of the Atropine Sulfate Tablet

The Dysurgal tablet is characterized by its oral route of administration, allowing the Atropine Sulfate to be absorbed systemically to treat internal spasms throughout the body. The medication's identity as a single-ingredient product confirms that its therapeutic effect is highly focused on its anticholinergic properties, making it a targeted therapy where high-potency vagal inhibition is required.

Regulatory References

What side effects are possible with Dysurgal?

Possible Side Effects and Safety Information

Dysurgal (Atropine Sulfate) is an anticholinergic agent, and its documented adverse reaction profile is primarily related to its effect on the nervous system, eyes, and smooth muscles. Side effects are typically dose-related and defined by government regulatory agencies (e.g., FDA and EMA) according to their frequency and the system-organ class affected.

Frequency-Classified Adverse Reactions

The following are examples of adverse reactions listed in official documents:

Frequency Classification	Examples of Documented Effects
Common (1 in 100 to 1 in 10)	Dry mouth, blurred vision, photophobia, headache, confusion, tachycardia, flushing, constipation, and urinary retention.
Very Common (1 in 10 or more)	Anhidrosis (reduced sweating), urticaria, and skin rash.

System-Organ Class Effects

Adverse effects are documented across several systems, including Eye Disorders (e.g., mydriasis, loss of accommodation), Cardiac Disorders (e.g., palpitations, arrhythmias), Gastrointestinal Disorders (e.g., nausea, vomiting, paralytic ileus), and Skin and Subcutaneous Tissue Disorders (e.g., dry skin, anhidrosis).

Serious Adverse Reactions and Safety Constraints

Documented serious adverse reactions, although rare, include anaphylaxis, precipitation of acute glaucoma in susceptible individuals, and complete urinary retention. The regulatory safety information emphasizes that certain populations are more susceptible to adverse effects, including older adults (confusion, difficulty in urination) and small children (hyperthermia). Due to the potential for anhidrosis, patients are cautioned to avoid excessive exercise and heat exposure.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Dysurgal (Atropine Sulfate) results in a defined pattern of clinical manifestations and can lead to severe systemic outcomes. The presence of any toxic signs requires that a patient seek immediate medical attention for definitive medical care.

Documented Overdose Manifestations

System	Signs and Symptoms
CNS	Delirium, excitement, hallucinations, tremor, coma, convulsions.
Cardiovascular	Tachycardia (rapid heartbeat), palpitations, circulatory collapse.
Peripheral	Dilated pupils (mydriasis), hot dry skin, hyperpyrexia (high fever), urinary retention.

Required Emergency Actions

Severe overdose is associated with the potential for respiratory failure and death due to medullary paralysis. In case of suspected toxic overdosage, symptomatic and supportive care are indicated. The official prescribing information cites Physostigmine as an antidote that may be administered to rapidly abolish severe central nervous system effects, such as delirium and coma. Other management includes using cooling measures to manage hyperpyrexia, and providing artificial respiration with oxygen if breathing is depressed. Pediatric patients are noted to be more susceptible to toxic effects, and 10 mg or less may be fatal in children.

Therapeutic Uses of Dysurgal

Quick Facts: Uses of Dysurgal

Supports the management of spasms (colic) in the gastrointestinal area.
May be used to address spasms affecting the biliary tract.
Associated with the treatment of spasms in the urinary tract.
Helps reduce secretions from the stomach and pancreas.

Dysurgal is a medication that supports the management of certain conditions characterized by involuntary muscular contractions, known as spasms, within the body. Its therapeutic use is indicated for the treatment of visceral spasms located in the gastrointestinal, biliary, and urinary tracts. These spasms may present as painful colic in these systems.

In addition to its role in spasm relief, Dysurgal helps reduce excessive secretory activity. It may be administered to lessen secretions produced by the stomach and the pancreas, contributing to its overall therapeutic effect in these areas. The medication’s established and approved indications are based on its properties which may contribute to the relief of symptoms related to these conditions. Patients should consult a qualified healthcare professional to determine if this therapy is appropriate for their specific medical context.

Eligibility and Restrictions for Use

Eligibility and Contraindications for Dysurgal

Dysurgal (Atropine Sulphate) is officially indicated for individuals experiencing spasms or colic in the gastrointestinal, biliary, and urinary tracts, and for the inhibition of secretions from the stomach and pancreas. Its use is generally established in children (2+ years), adolescents, and adults.

Formal Contraindicated Populations

Use of Dysurgal is strictly contraindicated and must be avoided in patients with:

Acute congestive glaucoma
Certain tachycardiac cardiac arrhythmias and coronary stenosis
Conditions causing mechanical obstruction or enlargement of the gastrointestinal tract, such as paralytic ileus or megacolon
Obstructive urinary tract diseases or bladder emptying disorders with postvoidal residual urine (e.g., due to prostatic hypertrophy)
Myasthenia gravis or acute pulmonary oedema
Pre-eclampsia
Known hypersensitivity to Atropine or other anticholinergics

Populations Requiring Special Care

Special care and continuous monitoring are required for specific patient groups due to heightened sensitivity to the drug:

Infants and small children (up to 2 years old) and older adults (over 65 years) may require dose adjustments.
Patients with fever or under high ambient temperatures (sauna/hot baths should be avoided).
Individuals with heart failure, hypertension, hyperthyreosis, or who have recently suffered a heart attack.
Patients with Down's Syndrome.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dysurgal’s official interaction profile is defined by the core properties of Atropine Sulfate, primarily its strong anticholinergic activity and its resulting effect on gastrointestinal motility. The regulatory documentation identifies specific medicinal products and timing constraints that necessitate careful consideration.

The co-administration with Monoamine Oxidase Inhibitors (MAOI) is generally noted as a high-risk combination due to the potential to precipitate a hypertensive crisis.

Interaction Type	Interacting Agent	Official Regulatory Statement
Pharmacodynamic	Other Anticholinergic Agents (e.g., Tricyclic Antidepressants, Antihistamines)	Co-administration leads to additive anticholinergic effects.
Pharmacodynamic	Alcohol (Ethanol)	May result in additive central nervous system (CNS) depression.
Exposure Alteration	Antacids	Decrease the gastrointestinal absorption of oral Atropine.
Exposure Alteration	Digoxin (slow dissolving tablets)	Slowed gut transit may lead to increased serum Digoxin levels.
Timing Constraint	Antacids	Oral Atropine must be administered at least 1 hour before Antacids.
Timing Constraint	Ketoconazole	Oral Atropine must be administered at least 2 hours after Ketoconazole to avoid reducing its absorption.

Additionally, substances that inhibit metabolism, such as certain organophosphorous pesticides, are documented to interfere with Atropine’s clearance. For specific formulations, the slowed gastrointestinal transit can potentiate adverse effects; this is officially noted for co-administration with oral Potassium Chloride (wax-matrix tablets). The effect of Atropine may also be potentiated by Pralidoxime.

Mechanism of Action

Dysurgal's active component, atropine sulfate, functions as a competitive, reversible antagonist across all subtypes of muscarinic acetylcholine receptors (M1 through M5). The drug binds to these receptors located on target tissues, including smooth muscle (gastrointestinal, urinary, and bronchial) and exocrine glands, thereby blocking the endogenous neurotransmitter acetylcholine from initiating a signal. Intracellularly, this blockade prevents the typical acetylcholine-mediated pathway, which involves G-protein coupling leading to changes in second messenger systems like cyclic adenosine monophosphate (cAMP) and inositol trisphosphate (IP3). In smooth muscle cells, the resulting downstream cascade includes the inhibition of calcium release and influx, leading to a state of hyperpolarization and reduced excitability. The system-level physiological consequence of muscarinic antagonism includes generalized parasympatholytic effects, resulting in decreased peristaltic motility in the gastrointestinal and urinary tracts, and inhibition of various glandular secretions, such as gastric, pancreatic, and salivary.

Dosage and Administration Information

How to Use Dysurgal

Dysurgal (Atropine Sulfate) is an anticholinergic agent formulated as an oral tablet for systemic administration. The instructions for use are structured around specific dose limits and frequency.

Administration and Dosing

Category	Official Administration Guideline
Route of Administration	Oral
Standard Adult Dose	A single dose ranges from 0.5 mg to 1 mg (one to two tablets).
Maximum Frequency	The tablet may be administered up to three times per day (3x daily use).
Maximum Daily Total	The maximum recommended total daily dose for adults and adolescents (15 years) is 3 mg of Atropine Sulfate.

Contextual Use Instructions

For proper administration, the tablet must be consumed whole with a sufficient quantity of liquid, such as a glass of water.

Treatment duration for Dysurgal is determined by the duration of the patient's symptoms, establishing a symptom-contingent use pattern. The medication is not intended for fixed-schedule long-term use unless directed by a prescribing professional.

Population-Specific Dosage

Dosage requires specific adjustment based on age group. For school children (6–14 years), the maximum daily total dose is 1.5 mg. Young children are prescribed a lower maximum daily total dose of 0.75 mg. Older adults (65 years) are noted as a population particularly sensitive to the active ingredient, necessitating careful dose consideration.

Recent Clinical Evidence

Research evidence / Overview of studies for Dysurgal

Evidence for Spasm Exploration in the Gastrointestinal, Biliary, and Urinary Tracts

This section will summarize the types of clinical studies, primarily older Randomized Controlled Trials (RCTs) and modern systematic reviews, that form the basis for exploring the oral tablet's use in conditions characterized by episodic manifestations like involuntary spasms (colic) in visceral organs. It will describe the high-level outcomes measured, such as pain intensity and the need for follow-up care.

The core of the research for Dysurgal research examined its application in conditions characterized by episodic manifestations like acute colic. The evidence available to regulators primarily stems from older, short-term RCTs which used in research exploring how symptoms change over time in adult populations presenting with acute spasms. These studies generally focused on outcomes related to physical discomfort, such as tracking measurements of pain intensity and how symptoms evolved over defined, short time intervals, rather than long-term effects.

When compared to placebo or other treatments, the research explored patterns of change measured by standardized instruments. These findings describe patterns observed in the studies related to the proportion of patients who required follow-up or rescue medication shortly after the initial intervention. However, it is important to note that the evidence quality varies across studies, and findings related to biliary pain was observed in some studies to be less consistent than for other types of spasms. Furthermore, a substantial portion of the historical research base studies monitored patients receiving the active agent through injection, and the relationship between those data and the effect of the oral tablet long-term effects are not fully established.

⏱️ Overview of Study Duration and Long-Term Follow-up

This part will detail the typical duration of observation in the key clinical trials, highlighting that the primary evidence relates to short-term, acute symptom change. It will outline what has been observed so far and what remains uncertain regarding the durability of response and any extended-duration data for the oral tablet.

Research studies explored episodic or acute changes in patient symptoms, meaning the follow-up durations were limited. Most trials and evidence summaries focused on outcomes within the first 30 minutes to 24 hours after administration was monitored. This short duration reflects the acute, temporary nature of the symptoms the research examined.

Consequently, long-term effects are not fully established for the oral formulation of Dysurgal. There is limited information for long-term outcomes that would contribute to understanding the effect of extended use on the frequency of spasm recurrence or changes in outcomes reflecting daily functioning or activity level over many months. The available evidence contributes to the broader evidence landscape, but does not provide comprehensive insight into durability of response.

Evidence Gaps and Areas of Uncertainty

This final part will synthesize the key limitations in the research base, including the reliance on older data and studies using non-oral administration routes. It will clarify the main areas of uncertainty, such as the lack of contemporary comparative data and long-term research using the oral formulation.

The research available for Dysurgal highlights what is known — and what is still uncertain. One primary limitation is the age of the core data, as many of the foundational studies were conducted decades ago and precede modern, standardized methods for clinical trials.

Also, comparative evidence is lacking from recent, large-scale studies that directly compare the oral agent compared to non-anticholinergic treatments widely used today for acute pain relief. This means the evidence is limited when attempting to fully position the agent within the current treatment landscape.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Dysurgal (FAQ)

Q: Does Dysurgal have any long-term side effects?

Official prescribing information notes that the core research for the oral tablet focused on short-term outcomes, typically within the first 24 hours of use, and long-term effects are not fully established.

However, official safety documents list important adverse reactions, such as the potential to precipitate acute glaucoma or cause complete urinary retention, which are generally related to its anticholinergic properties.

Q: Is it okay to crush or chew the tablet to make it easier to swallow?

The official administration instructions are very specific about how the medicine should be taken. The prescribing information specifies that the tablet should be swallowed whole with a sufficient amount of liquid, such as a glass of water.

Q: How does Dysurgal interact with alcohol?

The regulatory information indicates that taking Dysurgal with alcohol (ethanol) may result in additive central nervous system (CNS) depression.

This means that the combination may increase effects like drowsiness, dizziness, or impaired coordination, which is noted as an important consideration in the official labeling.

Q: What should I do if I miss a dose of Dysurgal?

Official guidance for this type of medication generally states that if a dose is missed, it should be disregarded, and the patient should continue with the next scheduled dose at the usual time.

The product information cautions that a double dose should not be taken to compensate for the missed dose.

Q: Is Dysurgal safe to take during pregnancy?

Regulatory information indicates that the active ingredient, Atropine, is known to cross the placental barrier.

There are limited comprehensive studies on use in pregnant women, and the product label requires a careful assessment of the potential benefits against any potential risks to the fetus before use.

Q: What should I do in case of an overdose?

The official product information specifies that in the event of a suspected overdose, immediate medical attention is required.

Contacting a poison control center or emergency services is necessary, as the treatment for an overdose requires specific medical care and supervision.

How should Dysurgal be stored and disposed of?

The storage and disposal of Dysurgal (atropine sulfate oral tablets) are governed by specific regulatory requirements to maintain product integrity and ensure safety.

Storage Condition	Requirement
Temperature	Store below 25 C (77 F).
Protection	Must be protected from light.

These conditions are essential to support the product's stability. For safety, the medicine must be stored out of the sight and reach of children and should be kept in a child-resistant container. Unused or expired Dysurgal must be disposed of according to local regulations and should not be discarded in household waste or flushed down wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Germany

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z